Comments

Barinthus Biotherapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Barinthus Biotherapeutics (BRNS) operate in?

Barinthus Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

BRNSNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$1.03

0.044.04%

At close: -

$1.02

-0.01-0.97%

After Hours: Mar 13, 7:13 AM EDT

Q4 2024 Earnings were released on Thu Mar 20th, before the market open

Barinthus Biotherapeutics (BRNS) Forecast

News Earnings Barinthus Biotherapeutics (BRNS) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Barinthus Biotherapeutics Stock Price, Quotes and Forecasts | NASDAQ:BRNS | Benzinga

Explore Barinthus Biotherapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for BRNS.

Open	$0.99
Close	$1.03
Volume / Avg.	8.46K / 33.53K
Day Range	$0.99 - $1.07
52 Wk Range	0.80 - 4.16
Market Cap	$40.20M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	52
Short Interest	0.05%
Days to Cover	1

Recent News

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.

Vandana Singh

Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates

Synlogic, Inc. (NASDAQ: SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.

Zacks

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Sep 24

Oct 24

Nov 24

Jan

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$0.99
Close	$1.03
Volume / Avg.	8.46K / 33.53K
Day Range	$0.99 - $1.07
52 Wk Range	0.80 - 4.16
Market Cap	$40.20M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	52
Short Interest	0.05%
Days to Cover	1

About Barinthus Biotherapeutics Plc.

Sector

Health Care

Industry

Biotechnology

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Barinthus Biotherapeutics (BRNS) stock?

You can purchase shares of Barinthus Biotherapeutics (NASDAQ:BRNS) through any online brokerage.

View our list of the best stock brokerages

Who are Barinthus Biotherapeutics (BRNS) competitors?

Other companies in Barinthus Biotherapeutics’s space includes: Estrella Immunopharma (NASDAQ:ESLA), bluebird bio (NASDAQ:BLUE), OS Therapies (AMEX:OSTX), CollPlant Biotechnologies (NASDAQ:CLGN) and Agenus (NASDAQ:AGEN).

What is the forecast, or price target, for Barinthus Biotherapeutics (BRNS) stock?

Barinthus Biotherapeutics has a consensus price target of $5.17.

What is the current price for Barinthus Biotherapeutics (BRNS)?

The stock price for Barinthus Biotherapeutics (NASDAQ: BRNS) is $1.02 last updated March 13, 2025 at 7:13 AM EDT.

Does Barinthus Biotherapeutics (BRNS) pay a dividend?

There are no upcoming dividends for Barinthus Biotherapeutics.

When is Barinthus Biotherapeutics (NASDAQ:BRNS) reporting earnings?

Barinthus Biotherapeutics’s Q1 earnings are confirmed for Monday, May 12, 2025.

Is Barinthus Biotherapeutics (BRNS) going to split?

There is no upcoming split for Barinthus Biotherapeutics.

What sector and industry does Barinthus Biotherapeutics (BRNS) operate in?

Barinthus Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.